Čeština | Dansk | Deutsch | English | Español | Français | Italiano | Nederlands | Norsk | Polski | Português | Pусский | Suomi | Svenska | US
Euro Huntington's disease network [logo]
Biomarkers - Dates - Meeting September 2005 -

Manchester, September 9th 2005


11:00 – 11:15
Dr. Sarah Tabrizi
A brief overview of biomarkers in Huntington’s disease andwhat constitutes the ideal biomarker.

11:15 –11:30
Presentations on Non-imaging Biomarkers Approaches in Huntington’s disease
Nature and Progress of the High Q Sponsored Biomarkers Projects.
Allan Tobin, High Q Foundation

11:30 –11:45
Metabonomic Approaches to Identification of Biomarkers in Huntington’s disease.
Elaine Holmes, Imperial College, London

11:45 – 12:00
Cambridge HD Researchers’ Approaches to Identification of Biomarkers in HD
Andrew Michel, University of Cambridge
12:00 – 12:15
Identification of CSF orexin levels as a biomarker for Huntington’s disease.
Asa Peterson, Lund University, Sweden

12:15- 12:30
Abnormalities of the HPA Axis in Huntington’s disease.
Maria Bjorkqvist, Lund University, Sweden

12:30 – 12:45
Epigenetic Gene Control Mechanisms in the Development and Progression of Huntington’s disease – how this may be useful in identification of biomarkers in Huntington’s disease.
Pernette Verschure, University of Amsterdam, NDL

Approx time for buffet lunch

13.15 – 13.30

Tracking Biomarkers in Mouse Pre-clinical Trials
Gillian Bates, King’s College London

Proteomic markers of Neurodegeneration in mouse models of disease.
Claus Zabel, University of Berlin
Proteomic Approaches to Biomarker Identification in Huntington’s disease, and how interlinking current studies with HD imaging studies is important
Sarah Tabrizi, Institute of Neurology, London

Using the Best-Balance Constraint Procedure (BBCP) in the interpretation of HD microarray data across species: preliminary results
Christian Neri, Department of Genomic Biology, Inserm, Paris

Microarray Approaches to Biomarker Identification to HD I
Angela Hodges, University of Cardiff

Microarray Approaches to Biomarker Identification to HD II
Ruth Luthi-Carter,University of Lausanne

Group Discussion
on recent papers
Strand et al. Gene expression in Huntington's disease skeletal muscle: a potential biomarker.
Hum Mol Genet. 2005 Jul 1;14(13):1863-76.
Borovecki et al Proc Natl Acad Sci U S A. 2005 Aug
Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease.

These will be discussed by the whole working party but will be led by Ruth Luthi-Carter, Angela Hodges and Lesley Jones, all who have expertise in array approaches. They will evaluate these two papers and we will all discuss how the data should be validated.

Over coffee
General Group
  • Collection of Samples within Euro-HD – blood, urine, muscle and CSF and validation of small studies – how to move forward
  • Comparing the use of imaging with the wet biomarkers approach
  • How to take forward identification of Biomarkers within the Euro- HD consortium.